AAPL331.97-1.29 (-0.39%) ▼|ABBV256.42+2.03 (+0.80%) ▲|ABT99.71+0.88 (+0.89%) ▲|ACN144.29-0.32 (-0.22%) ▼|ADBE239.46+4.15 (+1.76%) ▲|AMAT532.95-27.98 (-4.99%) ▼|AMD497.29-3.65 (-0.73%) ▼|AMGN362.47-9.12 (-2.45%) ▼|AMT169.58+0.66 (+0.39%) ▲|AMZN247.21-2.68 (-1.07%) ▼|AVGO372.93-1.52 (-0.41%) ▼|AXP355.26-6.31 (-1.75%) ▼|BA214.76+0.42 (+0.19%) ▲|BAC61.25-0.24 (-0.39%) ▼|BKNG181.65-2.96 (-1.60%) ▼|BLK1,074.11-12.94 (-1.19%) ▼|BMY60.70+0.19 (+0.31%) ▲|BNY157.22-3.64 (-2.26%) ▼|BRK-B491.19-1.93 (-0.39%) ▼|C129.90-1.81 (-1.37%) ▼|CAT885.83+8.66 (+0.99%) ▲|CL92.87-1.20 (-1.28%) ▼|CMCSA23.81-0.30 (-1.22%) ▼|COF208.72-3.21 (-1.51%) ▼|COP114.12+1.28 (+1.13%) ▲|COST938.21-7.37 (-0.78%) ▼|CRM171.83-0.85 (-0.49%) ▼|CSCO112.82+3.16 (+2.88%) ▲|CVS106.95+0.45 (+0.42%) ▲|CVX186.71+2.85 (+1.55%) ▲|DE597.34-1.64 (-0.27%) ▼|DHR203.62-1.39 (-0.68%) ▼|DIS97.35-2.37 (-2.37%) ▼|DUK124.85-1.26 (-1.00%) ▼|EMR139.80+0.72 (+0.52%) ▲|FDX313.83-4.37 (-1.37%) ▼|GD368.09-0.73 (-0.20%) ▼|GE349.93+4.20 (+1.21%) ▲|GEV1,059.27+23.05 (+2.22%) ▲|GILD134.97-1.33 (-0.98%) ▼|GM76.61-1.11 (-1.43%) ▼|GOOG342.44-11.37 (-3.21%) ▼|GOOGL342.96-11.51 (-3.25%) ▼|GS1,074.05-21.41 (-1.95%) ▼|HD340.21-7.81 (-2.24%) ▼|HON225.41-0.92 (-0.41%) ▼|IBM212.15-6.90 (-3.15%) ▼|INTC96.04-0.94 (-0.97%) ▼|INTU293.29-1.50 (-0.51%) ▼|ISRG349.60-52.73 (-13.11%) ▼|JNJ253.00+3.03 (+1.21%) ▲|JPM343.17+0.02 (+0.01%) ▲|KO81.08-3.84 (-4.52%) ▼|LIN514.69-6.06 (-1.16%) ▼|LLY1,174.55+5.38 (+0.46%) ▲|LMT511.41-2.11 (-0.41%) ▼|LOW209.98-6.18 (-2.86%) ▼|LRCX312.28-8.68 (-2.70%) ▼|MA542.57-8.97 (-1.63%) ▼|MCD267.67-5.79 (-2.12%) ▼|MDLZ60.82-0.60 (-0.98%) ▼|MDT83.03-0.53 (-0.63%) ▼|META646.96-17.58 (-2.65%) ▼|MMM160.78-1.00 (-0.62%) ▼|MO74.10+1.07 (+1.47%) ▲|MRK127.29-0.34 (-0.27%) ▼|MS215.35-3.03 (-1.39%) ▼|MSFT395.88-5.22 (-1.30%) ▼|MU876.57+23.37 (+2.74%) ▲|NEE88.71-0.64 (-0.72%) ▼|NFLX69.34-5.02 (-6.75%) ▼|NKE43.72-0.86 (-1.92%) ▼|NOW104.38+0.37 (+0.35%) ▲|NVDA203.66-3.74 (-1.80%) ▼|ORCL127.24+3.03 (+2.44%) ▲|PEP136.62-2.81 (-2.02%) ▼|PFE25.05-0.10 (-0.38%) ▼|PG149.58-1.93 (-1.27%) ▼|PLTR134.04-0.41 (-0.30%) ▼|PM191.26+1.42 (+0.75%) ▲|QCOM170.40-0.27 (-0.16%) ▼|RTX194.62+0.26 (+0.13%) ▲|SBUX105.47-2.90 (-2.68%) ▼|SCHW101.87-0.93 (-0.90%) ▼|SO95.38-0.70 (-0.72%) ▼|SPG227.69-0.80 (-0.35%) ▼|T21.78-0.20 (-0.91%) ▼|TMO533.17-10.02 (-1.84%) ▼|TMUS191.53-1.32 (-0.68%) ▼|TSLA381.86-9.21 (-2.35%) ▼|TXN283.80-7.43 (-2.55%) ▼|UBER72.75-1.29 (-1.74%) ▼|UNH434.62+11.24 (+2.65%) ▲|UNP300.56+1.14 (+0.38%) ▲|UPS117.74+0.56 (+0.48%) ▲|USB63.50-0.52 (-0.80%) ▼|V358.72-6.42 (-1.76%) ▼|VZ43.51-0.37 (-0.84%) ▼|WFC87.43-0.64 (-0.73%) ▼|WMT114.48-0.47 (-0.41%) ▼|XOM147.91+1.96 (+1.34%) ▲|AAPL331.97-1.29 (-0.39%) ▼|ABBV256.42+2.03 (+0.80%) ▲|ABT99.71+0.88 (+0.89%) ▲|ACN144.29-0.32 (-0.22%) ▼|ADBE239.46+4.15 (+1.76%) ▲|AMAT532.95-27.98 (-4.99%) ▼|AMD497.29-3.65 (-0.73%) ▼|AMGN362.47-9.12 (-2.45%) ▼|AMT169.58+0.66 (+0.39%) ▲|AMZN247.21-2.68 (-1.07%) ▼|AVGO372.93-1.52 (-0.41%) ▼|AXP355.26-6.31 (-1.75%) ▼|BA214.76+0.42 (+0.19%) ▲|BAC61.25-0.24 (-0.39%) ▼|BKNG181.65-2.96 (-1.60%) ▼|BLK1,074.11-12.94 (-1.19%) ▼|BMY60.70+0.19 (+0.31%) ▲|BNY157.22-3.64 (-2.26%) ▼|BRK-B491.19-1.93 (-0.39%) ▼|C129.90-1.81 (-1.37%) ▼|CAT885.83+8.66 (+0.99%) ▲|CL92.87-1.20 (-1.28%) ▼|CMCSA23.81-0.30 (-1.22%) ▼|COF208.72-3.21 (-1.51%) ▼|COP114.12+1.28 (+1.13%) ▲|COST938.21-7.37 (-0.78%) ▼|CRM171.83-0.85 (-0.49%) ▼|CSCO112.82+3.16 (+2.88%) ▲|CVS106.95+0.45 (+0.42%) ▲|CVX186.71+2.85 (+1.55%) ▲|DE597.34-1.64 (-0.27%) ▼|DHR203.62-1.39 (-0.68%) ▼|DIS97.35-2.37 (-2.37%) ▼|DUK124.85-1.26 (-1.00%) ▼|EMR139.80+0.72 (+0.52%) ▲|FDX313.83-4.37 (-1.37%) ▼|GD368.09-0.73 (-0.20%) ▼|GE349.93+4.20 (+1.21%) ▲|GEV1,059.27+23.05 (+2.22%) ▲|GILD134.97-1.33 (-0.98%) ▼|GM76.61-1.11 (-1.43%) ▼|GOOG342.44-11.37 (-3.21%) ▼|GOOGL342.96-11.51 (-3.25%) ▼|GS1,074.05-21.41 (-1.95%) ▼|HD340.21-7.81 (-2.24%) ▼|HON225.41-0.92 (-0.41%) ▼|IBM212.15-6.90 (-3.15%) ▼|INTC96.04-0.94 (-0.97%) ▼|INTU293.29-1.50 (-0.51%) ▼|ISRG349.60-52.73 (-13.11%) ▼|JNJ253.00+3.03 (+1.21%) ▲|JPM343.17+0.02 (+0.01%) ▲|KO81.08-3.84 (-4.52%) ▼|LIN514.69-6.06 (-1.16%) ▼|LLY1,174.55+5.38 (+0.46%) ▲|LMT511.41-2.11 (-0.41%) ▼|LOW209.98-6.18 (-2.86%) ▼|LRCX312.28-8.68 (-2.70%) ▼|MA542.57-8.97 (-1.63%) ▼|MCD267.67-5.79 (-2.12%) ▼|MDLZ60.82-0.60 (-0.98%) ▼|MDT83.03-0.53 (-0.63%) ▼|META646.96-17.58 (-2.65%) ▼|MMM160.78-1.00 (-0.62%) ▼|MO74.10+1.07 (+1.47%) ▲|MRK127.29-0.34 (-0.27%) ▼|MS215.35-3.03 (-1.39%) ▼|MSFT395.88-5.22 (-1.30%) ▼|MU876.57+23.37 (+2.74%) ▲|NEE88.71-0.64 (-0.72%) ▼|NFLX69.34-5.02 (-6.75%) ▼|NKE43.72-0.86 (-1.92%) ▼|NOW104.38+0.37 (+0.35%) ▲|NVDA203.66-3.74 (-1.80%) ▼|ORCL127.24+3.03 (+2.44%) ▲|PEP136.62-2.81 (-2.02%) ▼|PFE25.05-0.10 (-0.38%) ▼|PG149.58-1.93 (-1.27%) ▼|PLTR134.04-0.41 (-0.30%) ▼|PM191.26+1.42 (+0.75%) ▲|QCOM170.40-0.27 (-0.16%) ▼|RTX194.62+0.26 (+0.13%) ▲|SBUX105.47-2.90 (-2.68%) ▼|SCHW101.87-0.93 (-0.90%) ▼|SO95.38-0.70 (-0.72%) ▼|SPG227.69-0.80 (-0.35%) ▼|T21.78-0.20 (-0.91%) ▼|TMO533.17-10.02 (-1.84%) ▼|TMUS191.53-1.32 (-0.68%) ▼|TSLA381.86-9.21 (-2.35%) ▼|TXN283.80-7.43 (-2.55%) ▼|UBER72.75-1.29 (-1.74%) ▼|UNH434.62+11.24 (+2.65%) ▲|UNP300.56+1.14 (+0.38%) ▲|UPS117.74+0.56 (+0.48%) ▲|USB63.50-0.52 (-0.80%) ▼|V358.72-6.42 (-1.76%) ▼|VZ43.51-0.37 (-0.84%) ▼|WFC87.43-0.64 (-0.73%) ▼|WMT114.48-0.47 (-0.41%) ▼|XOM147.91+1.96 (+1.34%) ▲|
30.2 C
New York
Friday, July 17, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Readout – Prime Minister Carney meets with Prime Minister of the United Kingdom Sir Keir Starmer

OTTAWA, ON, June 15, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Prime Minister of the United Kingdom (UK), Sir...

Zenobē and Brampton lead CA$4 billion initiative to electrify transit bus fleet in landmark UK-Canada collaboration

CA$4B to fund one of North America's largest single zero-emission bus initiatives Initiative expected to support 5,000 direct and indirect jobs across U.K. and...

Coding Hype Threatens Engineers — Again

On a screen in Kirkland, Washington, Steve Yegge, an old hand in software engineering, watches as AI churns out code like a machine on...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

CIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Civitas Resources, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Civitas Resources, Inc. (“Civitas” or “the Company”) (NYSE: CIVI) and certain of its officers.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Announcement regarding the governance of Renault Group

Announcement regarding the governance
of Renault Group

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers